【ChiCTR2600121733】Does the minimally invasive direct anterior approach result in less postoperative muscle damage and a faster functional recovery trajectory compared with the minimally invasive direct lateral approach in patients undergoing primary uncemented total hip arthroplasty?
ChiCTR2600121733
结束
/
/
/
2026-04-02
/
/
Hip osteoarthritis
Does the minimally invasive direct anterior approach result in less postoperative muscle damage and a faster functional recovery trajectory compared with the minimally invasive direct lateral approach in patients undergoing primary uncemented total hip arthroplasty?
At MRI, the minimally invasive direct anterior approach produces less muscle alterations compared to the minimally invasive direct lateral approach in uncemented total hip arthroplasty: a prospective quasi-randomized study
The primary objective of this study is to compare postoperative muscle alterations between the minimally invasive direct anterior approach (DAA) and the minimally invasive direct lateral approach (DLA) in patients undergoing primary uncemented total hip arthroplasty, as assessed by magnetic resonance imaging at 12 months. Secondary objectives are to compare the trajectory of functional recovery and health-related quality of life between the two surgical approaches at 1, 3, 6, and 12 months postoperatively.
非随机对照试验
其它
This is a prospective quasi-randomized study. Allocation was determined according to predefined operative scheduling days. No computer-generated random sequence was used.
None.
This study received no external funding.
/
19;21
/
2022-01-05
2024-01-10
/
1. Adult patients undergoing primary THA for hip osteoarthritis 2. Eligibility for uncemented THA 3. Ability to complete clinical follow-up 4. Eligibility for MRI examination at 12 months；
请登录查看1. Hip fracture or post-traumatic arthritis 2. Inflammatory or autoimmune joint disease 3. Neuromuscular disorders 4. Active malignancy or chronic immunosuppression 5. Contraindications to MRI；
请登录查看Department of Orthopaedics and Traumatology, Sant’Andrea University Hospital, Sapienza University of Rome
/
Department of Orthopaedics and Traumatology, Sant’Andrea University Hospital, Sapienza University of Rome的其他临床试验
Sant’Andrea University Hospital的其他临床试验
最新临床资讯
-
大鹏制药临床III期成功
新药说2026-08-13
-
新一代 EGFR-TKI 首个全球 III 期成功
丁香园 Insight 数据库2026-08-13
-
体外诊断原料网2026-08-13
-
佰傲谷BioValley2026-08-13
-
久有基金2026-08-13
-
重庆宸安生物2026-08-13
-
UmabsDB2026-08-13
-
希格生科2026-08-13
-
bioSeedin柏思荟2026-08-13
-
智飞智讯2026-08-13
全球药物研发中心
全球研发数据与行业前沿情报
研发动态
相关报告
政策法规
-
2026-08-14
-
2026-08-14
-
2026-08-14
-
摩熵咨询 20 8
-
摩熵咨询 34 28
-
摩熵咨询 20 5
-
颁布机构：四川省经济和信息化厅、中共四川省委军民融合发展委员会办公室、四川省教育厅、四川省科学技术厅、四川省人力资源和社会保障厅、四川省卫生健康委员会、四川省医疗保障局、四川省中医药管理局、四川省药品监督管理局 2026-08-04
-
颁布机构：国家医保局 2026-07-31
-
颁布机构：国家药品审评中心（CDE） 2026-07-24
医药市场洞察中心
医药市场销售数据分析 · 智能洞察 · 竞争格局监测
-
医药市场销售数据分析 · 医院、实体药店、网上药店
-
市场竞争格局分析(靶点、药品类型、ATC大类)
市场动态
市场报告
政策法规
-
2026-08-14
-
2026-08-13
-
2026-08-13
-
摩熵咨询 35 36
-
摩熵咨询 28 39
-
摩熵咨询 34 18
-
颁布机构：国家市场监督管理总局 2026-08-10
-
颁布机构：国家市场监督管理总局 2026-05-29
-
颁布机构：国家市场监督管理总局 2026-05-29